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Purpose of review
Human parechoviruses (HPeVs) within the large and growing family of Picornaviridae
are common human pathogens associated with a wide spectrum of disease
presentations. Although 10 different HPeV types have been published to date, there is
increasing evidence for a specific role of HPeV type 3 (HPeV3) in severe neonatal
disease. In this review, we will describe both the disease associations and underlying
epidemiological and/or biological basis for the often marked differences in disease
outcomes between HPeV types.
Recent findings
Application of molecular-based diagnostic techniques has revealed an association
between neonatal sepsis, encephalitis and hepatitis with HPeV3 but not with other
parechovirus types. HPeV3 shows evidence for very recent emergence in human
populations as well as inferred differences in cellular receptor usage.
Summary
The recently discovered HPeV3 has been shown to play an important role in severe
neonatal infections, observations possibly linked to its very recent emergence or
possibly different cellular tropism that underlie its targeting of the most susceptible
individuals. HPeV infections are currently under-diagnosed and should be considered in
the clinical and diagnostic evaluation of severe neonatal disease presentations.
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Human parechoviruses (HPeVs) are small, nonenve-
loped, single-stranded and positive-sense RNA viruses
within the Parechovirus genus of the large Picornaviridae
family (Fig. 1). The HPeV genome is approximately 7400
bases in length, and encodes a single polyprotein flanked
by 50 and 30 untranslated regions (UTRs). The polypro-
tein is post-translationally cleaved into three structural
viral proteins (VP1–VP3) and seven nonstructural
proteins (2A–2C and 3A–3D) (Fig. 2).
The first two HPeV types, originally described as echo-
viruses 22 and 23 within the Enterovirus genus, were
isolated over 50 years ago, whereas a further eight HPeV
types known to infect human have been only very
recently identified. Infections are enteric and often
associated with mild gastrointestinal and respiratory
symptoms, although severe neonatal diseases including
sepsis, meningitis, encephalitis and hepatitis have been
described. Intriguingly, these more severe disease out-
comes have been specifically linked to infection with a
newly emergent HPeV type 3 (HPeV3). The recent
evidence for its greater pathogenicity in neonates andopyright © Lippincott Williams & Wilkins. Unautho
0951-7375  2010 Wolters Kluwer Health | Lippincott Williams & Wilkinsthe underlying differences in epidemiology and host
interactions will be the primary focus of this review.Human parechovirus infections
Human parechovirus infections are extremely wide-
spread worldwide but historically infrequently recog-
nized or diagnosed as a cause of human disease. Part
of the reason for this is the often inapparent or misunder-
stood nature of their infections that typically target
children under the age of 2 years, and difficulties with
their detection by traditional virus diagnostic techniques
such as virus isolation [3]. Indeed our current greater
understanding of the frequency and disease associations
of HPeVs has been gained through the recent develop-
ment of molecular detection methods. The widely used
reverse-transcriptase polymerase chain reaction (RT-
PCR) assay is much faster and has far greater sensitivity
and specificity, particularly for those HPeV variants
associated with more severe disease [4,5,6–10]. How-
ever, routinely used enterovirus RT-PCR will fail to
detect HPeVs due to genetic differences between these
viruses and thus HPeV-specific RT-PCR has to be used.
Primers targeting the highly conserved 50UTR allowrized reproduction of this article is prohibited.
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Figure 1 Evolutionary relationship of human parechovirus to other picornaviruses: classification into genera and species
Evolutionary tree of picornaviruses showing its division into 14 designated or proposed genera (enclosed within bubbles), and the human enterovirus
and parechovirus groups highlighted in dark gray. The tree was constructed by comparisons of amino acid sequences of the 3Dpol region [positions
5711–7252 in the prototypeHarris genome (accession number L02971)]. EMCV, encephalomyocarditis virus; ERAV, equine rhinitis virus; FMDV, foot
and mouth disease virus; HEV, human enterovirus; HPeV, human parechovirus; HRV: human rhinovirus. The status of the recently described group of
human enteric viruses labelled Klassevirus [1] is undecided and may be eventually included within the Kobuvirus genus.
Figure 2 Genome organization of human parechovirus
Genome organization of parechoviruses coding for a single polyprotein. This is cleaved to form structural (gray) and nonstructural proteins (light gray
and black) for replication and virus particle formation. The RGDmotif used for integrin binding and entry in HPeV1, 2, 4–6 is arrowed. Information on the
demonstrated or inferred functions of the individual virally encoded proteins are summarized in [2].
C226 Paediatric and neonatal infectionsequally sensitive detection of all known HPeV types,
whereas the amplification and sequencing of the highly
variable VP1 region enables reliable type identification of
HPeV-positive samples [9,11,12].
Human parechovirus types
The use of RT-PCR and molecular virus discovery
methods has dramatically increased our knowledge of
the prevalence, genetic diversity and range of clinical
presentations associated with different HPeV types.
HPeV types 1 and 2 (previously known as echovirus 22
and 23, respectively) were discovered in USA from chil-
dren with diarrhoea in 1956 [13]. HPeV3 was identified in
Japan from a 1-year-old child with transient paralysis,
fever and diarrhoea in 1999 [14] and almost simul-
taneously was also recovered from nasopharyngeal aspi-
rates of neonates with suspected sepsis in Canada [15].
Another new HPeV type, HPeV4, was isolated from a
stool sample of a neonate with febrile illness in the
Netherlands in 2002 [16], but has been since shown to
have circulated at least from the 1970s [17,18]. HPeV5
was first identified in USA in 1986 from a 2-year-old child
with high fever [19], but this virus was originally assigned
as HPeV2 based on incorrect neutralization data and has
only recently been classified as a fifth type based on
genetic analysis [18]. HPeV6 was isolated from a cere-
brospinal fluid (CSF) specimen of a 1-year-old child with
Reye’s syndrome in Japan [20]. Very recently HPeV7 was
identified from the stool sample of a healthy Pakistani
child who had been in contact with a case of acute flaccid
paralysis (AFP) [21], whereas screening a faecal sample
collection from Brazilian children with acute diarrhoea
revealed another novel HPeV type, HPeV8 [22]. The
remaining HPeV types shown to infect human (10 and
14) have been identified only very recently from the
Netherlands, Sri Lanka and Thailand [12,23,24]. The
host origin (human or primate) of the other unpublished
HPeV variants (types 9, 11–13) listed on http://www.
picornastudygroup.com/types/parechovirus/hpev.htm is
uncertain.
Epidemiology of human parechovirus infections
Despite the original detection of several of these virus
types in association with diarrhoea, neonatal febrile
illness and central nervous system (CNS) diseases, HPeV
primarily causes clinically inapparent or unrecognized
infections in young children. Through detection of anti-
bodies to HPeV, it has been shown that over 90% of
children have been infected with at least one HPeV type
by the age of 2 years [6,25]. Targeting of this age group is
also apparent by observations over 30 years ago that 60%
of 580 HPeV isolates originated from children under the
age of 1 year [26]. Similarly, surveillance data in the USA
between 1983 and 2005 revealed 73% of 456 HPeV1
infections and 68% of 34 HPeV2 infections occurred
under the age of 1 year [27], whereas in the Netherlandsopyright © Lippincott Williams & Wilkins. Unauthofrom 2000 onwards almost all HPeV1 and HPeV3 infec-
tions have been recorded in children under the age of
3 years [28,29]. Evidence for its high incidence in this
group was provided by a recent longitudinal community-
based study of Norwegian children under the age of 2,
where 11.3% of 1941 faecal samples were HPeV-positive
irrespective of presenting symptoms [30]. Remarkably,
there are only four studies in the current literature of
HPeV infections in individuals over the age of 10 years
[20,31–33]. Studies of disease complication of HPeV
must therefore take into account the high background
incidence and overwhelmingly clinically inapparent
nature of HPeV infections in young children.
Neonatal infections
The primary site of HPeV replication is thought to be the
respiratory and gastrointestinal tract; replication in the
intestine leads to prolonged shedding of infectious virus
in faeces readily detectable by virus isolation and RT-
PCR methods. In addition to faecal/oral transmission,
infections may also occur through respiratory routes, with
infection and virus shedding detectable in respiratory
secretions. Furthermore, virus can spread via the blood
stream to other organs causing systemic illness. HPeV
type 3 has been recently shown to be an important cause
of severe infections in very young children including
sepsis, encephalitis and hepatitis. These clinical mani-
festations overlap with those produced by enteroviruses,
and disease is often indistinguishable without specific
virological diagnosis.
To clinically exclude sepsis in newborns less than
90 days old with fever (defined as a temperature
>388C) is problematic, and a term ‘neonatal viral sepsis’
has been widely used to describe pyrexia in neonates
with a high fever without an identifiable bacterial cause.
Wolthers et al. [29] have defined sepsis-like viral illness
as fever or hypothermia with signs of circulatory and/or
respiratory dysfunction measured by tachycardia or
bradycardia, low blood pressure and decreased oxygen
saturation. However, study participants described as
having sepsis clinically but without fulfilling the above
criteria [29] and those without sufficient data provided
to define sepsis-like viral illness [11,15], are referred to
as suspected sepsis in the remainder of the review.
Furthermore, neonatal sepsis can range in severity from
a nonspecific febrile illness to potentially fatal multi-
system disease often with respiratory or gastrointestinal
symptoms, CNS involvementmanifesting as meningitis,
encephalitis ormeningoencephalitis, or have evidence of
hepatitis. Causative studies of neonatal sepsis during
the first month of life yielded a bacterial cause in
approximately 10–15% of patients, with the remaining
febrile neonates assumed to have a viral infection most
commonly caused by enterovirus [34]. However, the
potential role of HPeV as a cause of severe neonatalrized reproduction of this article is prohibited.
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atically investigated.
Several studies describe HPeV detection in association
with neonatal sepsis in studies from Canada, the Nether-
lands, UK and USA [11,15,28,31,33] and have also been
linked with meningitis in young children [35]. In a Dutch
study, HPeV was detected by real-time RT-PCR in 4.2%
of 761 CSF samples from children under the age of
5 years [28,29]. Most of these children presented with
defined or suspected sepsis-like illness (15/29 and 6/29,
respectively), whereas meningitis (3/29) or encephalitis
(1/29) were also seen. The median age of these HPeV-
positive children was 1.2 months. In a recent study from
Scotland, 14 from 1575 CSF samples were HPeV-positive
on screening by RT-PCR, each of which originated from
infants less than 3 months of age with suspected sepsis or
pyrexia. HPeV typing of these CSF samples revealed all
infection to be due to HPeV3, despite the circulation of
predominantly HPeV1 in the local community [11].
The incidence of severe HPeV3 infection (and of sus-
pected neonatal sepsis) followed the same biannual cycle
as noted previously from faecal samples [11,12,28,35],
with the highest frequency in 2008 (7.2%) exceeding that
of enteroviruses [11]. The association of HPeV3 with
neonatal sepsis is consistent with previous studies from
smaller sample numbers implicating this specific par-
echovirus type [10,36], and with the rarity of other
types [1,2,4,5] in sepsis cases [3,16–18,28,31].
Neonates with HPeV encephalitis present similarly to
enterovirus infection, the most frequent signs being fever,
seizures, irritability, rash and feeding problems [37]. A
recent study described 10 newborn infants with HPeV3
confirmed encephalitis, who all except one presented
clinically with seizures and had periventricular white mat-
ter changes confirmed by magnetic resonance imaging
[36]. Furthermore, pleocytosis was found in only 1 of
10 patients studied, and the protein and glucose levels
remained normal in all cases [37]. Normal CSF findings
can therefore be misleading when diagnosing neonatal
HPeV infection. The neurodevelopmental outcome was
variable with cerebral palsy in one, learning disability at 7
years of age in one, epilepsy in one, suspected develop-
mental abnormalities at 18 months in one and normal
neurodevelopment in six children [36]. Interestingly,
data from animal experiments suggest that enterovirus
infections acquired in the neonatal period may persist in
the CNS as a low-level, noncytolytic infection, causing
ongoing inflammatory lesions [38]. It might therefore be
speculated that these longer effects of HPeV infection in
neonatesmay similarly reflect ongoing damage to theCNS
arising from persistence.
HPeV3 was recently identified as a cause of neonatal
hepatitis-coagulopathy syndrome [39]. This neonateopyright © Lippincott Williams & Wilkins. Unauthpresented with high fever, and was found to have abnor-
mal liver enzymes 4 days later (AST 5421U/l and ALT
1207U/l). He also developed significant coagulopathy
and thrombocytopenia on hospital day 7, but within
9 days from admission his hepatitis, coagulopathy and
thrombocytopenia resolved. Hepatitis with coagulopathy
caused by HPeV3 has also been described in Scottish
neonatal twins [33]. As an emerging pathogen, HPeV3
(and other types) appears to display a wide variety of
clinical presentations including neonatal sepsis, menin-
gitis, encephalitis and hepatitis, and is probably more
common than previously suspected.
Infections with other parechovirus types
HPeV types 1, 2, 4 and 6 have been associated with
gastroenteritis in several different studies [40,41], but their
role as a cause of enteric disease is to be definitely estab-
lished. Detection in at least some cases most likely
represents asymptomatic carriage and is incidental to
gastroenteritis from another cause. Although HPeV1 has
been linked clearly with acute otitis media [42], the
association between HPeV types 1, 3, 4, 5 and 6 and
respiratory tract disease is less well defined [9,31,40]
and requires further studies to establish a causal relation-
ship. In addition to HPeV3, HPeV1 has been linked with
sporadic cases of aseptic meningitis [26], encephalitis [41],
encephalomyelitis [43] and flaccid paralysis [32], whereas
one of the HPeV2 strains was originally isolated from a
childwith asepticmeningitis [43].Anumberof case reports
and small studiespropose associations ofHPeVwith awide
range of other diseases, including lymphadenitis (HPeV4;
[20]), myositis (HPeV3; [17]), haemolytic uraemic
syndrome (HPeV1; [44]), myocarditis (HPeV1; [45,46]),
TORCH syndrome (HPeV4; [17]) and necrotizing enter-
ocolitis (HPeV1; [47]). In addition, case reports describe
HPeV1, HPeV3 andHPeV6 detection in sporadic cases of
AFP in children [14,20,32]. Reye’s syndrome, which is
characterized as an acute, non-inflammatory encephalo-
pathy with hepatic dysfunction and fatty infiltration, has
been similarly associated with lethal HPeV5 [18] and
HPeV6 infections [20]. Further studies, with improved
diagnostic assays, are required to determine the frequen-
cies of these disease associations relative to other viral and
non-viral causes.Treatment
The treatment of (neonatal) parechovirus infections is
primarily supportive in the absence of specific antiviral
therapy. The outcome of neonatal enterovirus infections
has been shown to benefit from immunoglobulin therapy
[48], although there are no data available to date to
support its use in HPeV infections. Pleconaril is the most
advanced antiviral treatment option for enteroviruses
targeting the attachment, entry and uncoating of enter-
oviruses, although only limited data on its efficacy fororized reproduction of this article is prohibited.
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In recent in-vitro studies, pleoconaril has been shown to
have no antiviral activity against HPeV (KW; unpub-
lished data) and new treatment strategies are likely to
be needed in future.Epidemiological and biological basis for
differences in pathogenicity
It is not known why HPeV3 is specifically associated with
severe neonatal infections, but the underlying basis may
be at least partly epidemiological. Infection and severe
systemic disease in neonates that follows may occur more
frequently in HPeV3 because frequencies of past infec-
tion with HPeV3 in adults may be lower than those of
other HPeV types. As a consequence, neonates and
young infants would not be protected as frequently by
maternal antibody after birth as they would be from
HPeV1 and possibly other types. This hypothesis is
supported by the much lower observed seroprevalence
of HPeV3 among women of child-bearing age in Japan
(68% [14]) compared to close to universal adult seropo-
sitivity for HPeV1 [6,25]. The median age of the children
infected with HPeV1 (6.6 months) was found to be sig-
nificantly higher than HPeV3 (1.3 months) [28], a finding
consistent with protection from HPeV1 by maternal anti-
body in the first half year of life. Indeed, more recent data
documentHPeV3 infections to occur almost exclusively in
children under the age of 3 months [11].
The lower adult seroprevalence of HPeV3 may be a
direct consequence of its more recent emergence than
HPeV and other types. Evidence for this is provided
by observations of extremely restricted within-type
sequence diversity of HPeV3 compared to other types.
Our recent measurement of evolutionary rates in the
VP3/VP1 regions of HPeV3 (2.83 103 substitutions
per site per year meaning 1 in 400 nucleotide changes
annually; over two-fold lower than for HPeV1) predicted
a common ancestor for all currently circulating variants of
HPeV3 in 1987 (range 1980–1992) [23], approximately
10 years before HPeV3 was first isolated (A308/99) in
Japan and in Canada [14,15]. Although comprehensive
worldwide genetic characterization of HPeV3 has yet to
be performed, these findings are nevertheless consistent
with the hypothesis for its relatively recent global spread
into a previously unexposed human population. Its emer-
gence may thus account for reduced adult exposure and
maternal antibody protection, and therefore its specific
targeting of neonates with immature immune systems
and lack of maternal antibody protection. Substantiation
of this hypothesis requires, however, much better data on
the actual frequencies of HPeV3 exposure and immunity
in countries where specific associations of this type with
neonatal disease have been demonstrated. It further
requires to be demonstrated that neonatal disease occursopyright © Lippincott Williams & Wilkins. Unauthospecifically in children of mothers seronegative for
HPeV3 at the time of birth, data missing from studies
of this phenomenon published to date. A recent case
report from Glasgow, UK [33] did, however, show that
infection of twins in the neonatal period with HPeV3
(presenting with pyrexia, rash and hepatitis) occurred
simultaneously with infection in the mother, consistent
with the hypothesis for a lack of maternal HPeV3
exposure underlying these severe disease outcomes.
A biological explanation, that HPeV types differ intrinsi-
cally in their tissue tropism and ability to spread systemi-
cally, is additionally possible. The ability of picornaviruses
to infect different cell types is primarily determined by
expression of membrane proteins that serve as receptors
for the virus. Many groups of picornaviruses, such as
enteroviruses and aphthoviruses (a group containing
foot-and-mouth disease virus; FMDV) show remarkable
variability in their receptor interactions, a feature that
likely extends to HPeV. In HPeV type 1, the C-terminus
of the VP1 capsid protein contains an arginine-glycine-
aspartic acid (RGD)motif [51,52] that is utilized by several
viruses to enable virus attachment through binding to cell
surface-expressed integrins. Among picornaviruses, these
include FMDV and the enteroviruses coxsackievirus A9
(CAV9) and a Barty strain of echovirus 9. HPeV1 utilizes
principally aVb1, aVb3, and aVb6 integrins as its receptors
[53–55]. Importantly, HPeV3 differs from most strains of
HPeV1 and other HPeV types by not encoding an RGD
motif in VP1 [14], implying use of a different cellular
receptor for entry, although what this might be has yet
to be determined.
The use of an alternative receptor may change the
cellular tropism of HPeV3, and conceivably lead to an
enhanced ability to spread and replicate in the CNS if the
putative receptor was expressed in neural tissue and the
integrins utilized byHPeV1 were not. On the basis of this
hypothesis, biological differences fromHPeV1might also
be expected in the more recently discovered HPeV types
[7–10,11,12–14] and a small subset of recently charac-
terized variants of HPeV1 and HPeV5 variants that also
lack RGD sequences in VP1 [12]. Future detailed clinical
investigation of infection outcomes with these viruses
will be required to evaluate the role of receptor use
variability in HPeV pathogenesis.Conclusion
The recent application of molecular methods for screen-
ing and type identification of HPeV has revealed greater
prevalence, genetic diversity and heterogeneity in its
epidemiology and clinical outcomes of infection than
had been previously revealed by cell culture-based diag-
nostic methods. The recently discovered HPeV3 has
since been shown to play an important role in severerized reproduction of this article is prohibited.
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hepatitis. The pathogenic nature of this HPeV type is
perhaps connected to its very recent emergence or dis-
tinct cellular tropism and virological properties that
underlie its targeting of a distinct group of susceptible
individuals. HPeV infections are currently under-diag-
nosed and should be considered, along with entero-
viruses, in the clinical and diagnostic evaluation of severe
neonatal disease presentations.References and recommended reading
Papers of particular interest, published within the annual period of review, have
been highlighted as:
 of special interest
 of outstanding interest
Additional references related to this topic can also be found in the Current
World Literature section in this issue (p. 278).
1 Greninger AL, Runckel C, Chiu CY, et al. The complete genome of klasse-
virus: a novel picornavirus in pediatric stool. Virol J 2009; 6:82.
2 Stanway G, Hyypia T. Parechoviruses. J Virol 1999; 73:5249–5254.
3 de Vries M, Pyrc K, Berkhout R, et al. Human parechovirus type 1, 3, 4, 5, and
6 detection in picornavirus cultures. J Clin Microbiol 2008; 46:759–762.
4 Baumgarte S, Souza Luna LK, Grywna K, et al. Prevalence, types, and RNA
concentrations of human parechoviruses, including a sixth parechovirus type,




Benschop K, Molenkamp R, van der Ham A, et al. Rapid detection of human
parechoviruses in clinical samples by real-time PCR. J Clin Virol 2008;
41:69–74.
This study demonstrates a high frequency of HPeV infection in children (3.8%),
detected by a newly developed real-time PCR from CSF samples. The study
suggests that HPeV screening of paediatric clinical samples should be included in
viral diagnostic assessment.
6 Joki-Korpela P, Hyypia T. Diagnosis and epidemiology of echovirus 22
infections. Clin Infect Dis 1998; 27:129–136.
7 Noordhoek GT,Weel JF, Poelstra E, et al.Clinical validation of a new real-time
PCR assay for detection of enteroviruses and parechoviruses, and implica-
tions for diagnostic procedures. J Clin Virol 2008; 41:75–80.
8 ObersteMS,Maher K, PallanschMA. Specific detection of echoviruses 22 and
23 in cell culture supernatants by RT-PCR. J Med Virol 1999; 58:178–181.
9 Harvala H, Robertson I, McWilliam Leitch EC, et al. Epidemiology and clinical
associations of human parechovirus respiratory infections. J Clin Microbiol
2008; 46:3446–3453.
10 Nix WA, Maher K, Johansson ES, et al. Detection of all known parechoviruses
by real time-PCR. J Clin Microbiol 2008; 46:2519–2524.
11

Harvala H, Robertson I, McWilliam Leitch C, et al. Aetiological role of human
parechovirus type 3 in neonatal sepsis identified by direct typing assay on
cerebrospinal fluid. J Infect Dis 2009; 199:1753–1760.
This study describes a method for direct HPeV typing of CSF samples. It
demonstrates directly the causative link between HPeV3 and severe neonatal
infections.
12 Benschop K, Thomas X, Serpenti C, et al. High prevalence of human
parechovirus genotypes in the Amsterdam region and the identification of
specific HPeV variants by direct genotyping of stool samples. J Clin Microbiol
2008; 46:3965–3970.
13 Wigand R, Sabin AB. Properties of ECHO types 22, 23 and 24 viruses. Arch
Gesamte Virusforsch 1961; 11:224–247.
14 Ito M, Yamashita T, Tsuzuki H, et al. Isolation and identification of a novel
human parechovirus. J Gen Virol 2004; 85:391–398.
15 Boivin G, Abed Y, Boucher FD. Human parechovirus 3 and neonatal infec-
tions. Emerg Infect Dis 2005; 11:103–105.
16 Benschop KS, Schinkel J, Luken ME, et al. Fourth human parechovirus
serotype. Emerg Infect Dis 2006; 12:1572–1575.
17 Schnurr D, Dondero M, Holland D, Connor J. Characterization of echovirus 22
variants. Arch Virol 1996; 141:1749–1758.
18 Al Sunaidi M, Williams CH, Hughes PJ, et al. Analysis of a new human
parechovirus allows the definition of parechovirus types and the identification
of RNA structural domains. J Virol 2007; 81:1013–1021.opyright © Lippincott Williams & Wilkins. Unauth19 Oberste MS, Maher K, Pallansch MA. Complete sequence of echovirus 23
and its relationship to echovirus 22 and other human enteroviruses. Virus Res
1998; 56:217–223.
20 Watanabe K, Oie M, Higuchi M, et al. Isolation and characterization of novel
human parechovirus from clinical samples. Emerg Infect Dis 2007; 13:889–
895.
21 Li L, Victoria J, Kapoor A, et al. Genomic characterization of novel human
parechovirus type. Emerg Infect Dis 2009; 15:288–291.
22 Drexler JF, Grywna K, Stocker A, et al. Novel human parechovirus from Brazil.
Emerg Infect Dis 2009; 15:310–313.
23 Calvert J, Chieochansin T, Benschop K, et al. The recombination dynamics of
human parechoviruses; investigation of type-specific differences in frequency
and epidemiological correlates. J Gen Virol 2010; Jan 20 [Epub ahead of
print].
24 Kim Pham NT, Trinh QD, Takanashi S, et al. Novel human parechovirus,
Sri Lanka. Emerg Infect Dis 2010; 16:130–132.
25 Tauriainen S, Martiskainen M, Oikarinen S, et al. Human parechovirus 1
infections in young children: no association with type 1 diabetes. J Med Virol
2007; 79:457–462.
26 Grist NR, Bell EJ, Assaad F. Enteroviruses in human disease. Prog Med Virol
1978; 24:114–157.
27 Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. Enterovirus
surveillance: United States, 1970–2005. MMWR Surveill Summ 2006;
55:1–20.
28 Benschop KS, Schinkel J, Minnaar RP, et al.Human parechovirus infections in
Dutch children and the association between serotype and disease severity.
Clin Infect Dis 2006; 42:204–210.
29

Wolthers KC, Benschop KS, Schinkel J, et al. Human parechoviruses as an
important viral cause of sepsislike illness andmeningitis in young children. Clin
Infect Dis 2008; 47:358–363.
This study describes HPeV as an important viral cause of sepsis-like illness and
meningitis in children younger than 5 years of age with incidences varying
significantly between years. Children with HPeV detected from CSF presented
with sepsis-like illness and meningitis, which led to hospitalization and often
unnecessary antibiotic treatment.
30 Tapia G, Cinek O, Witso E, et al. Longitudinal observation of parechovirus in
stool samples from Norwegian infants. J Med Virol 2008; 80:1835–1842.
31 Abed Y, Boivin G. Human parechovirus infections in Canada. Emerg Infect Dis
2006; 12:969–975.
32 Figueroa JP, Ashley D, King D, Hull B. An outbreak of acute flaccid paralysis in
Jamaica associated with echovirus type 22. J Med Virol 1989; 29:315–319.
33 Al Maamari K, Docherty K, Aitken C. ‘Twin’ viruses. J Clin Virol 2009; 44:vi.
34 Byington CL, Enriquez FR, Hoff C, et al. Serious bacterial infections in febrile
infants 1 to 90 days old with and without viral infections. Pediatrics 2004;
113:1662–1666.
35 van der Sanden S, de Bruin E, Vennema H, et al. Prevalence of human




Verboon-Maciolek MA, Groenendaal F, Hahn CD, et al. Human parechovirus
causes encephalitis with white matter injury in neonates. Ann Neurol 2008;
64:266–273.
This is the first study to demonstrate the white matter changes in neonatal
encephalitis caused by HPeV3. This study shows that white matter changes
can be visualized with cranial ultrasonography, but more detailed information is
obtained with magnetic resonance imaging. The clinical presentation is similar for
enterovirus and HPeV infection; both viruses should be investigated in atypical
presentation of neonatal seizures.
37

Verboon-Maciolek MA, Krediet TG, Gerards LJ, et al. Severe neonatal par-
echovirus infection and similarity with enterovirus infection. Pediatr Infect Dis J
2008; 27:241–245.
This study describes the similarity in clinical features of neonatal HPeV and
enterovirus infections. Thus neonates presenting with sepsis-like illness asso-
ciated with fever, seizures, irritability, rash and feeding problems should be
evaluated by both HPeV and enterovirus RT-PCR, since it is not possible to
distinguish neonatal HPeV from enterovirus infection clinically.
38 Feuer R, Ruller CM, An N, et al. Viral persistence and chronic immunopathol-
ogy in the adult central nervous system following Coxsackievirus infection
during the neonatal period. J Virol 2009; 83:9356–9369.
39

Levorson RE, Jantausch BA, Wiedermann BL, et al. Human parechovirus-3
infection: emerging pathogen in neonatal sepsis. Pediatr Infect Dis J 2009;
28:545–547.
This study presents clinical details of neonatal encephalitis and hepatitis-coagulo-
pathy syndrome caused by HPeV3, which is important for further understanding
HPeV disease.orized reproduction of this article is prohibited.
C230 Paediatric and neonatal infections40 Pajkrt D, Benschop KS, Westerhuis B, et al. Clinical characteristics of human
parechoviruses 4–6 infections in young children. Pediatr Infect Dis J 2009;
28:1008–1010.
41 Koskiniemi M, Paetau R, Linnavuori K. Severe encephalitis associated
with disseminated echovirus 22 infection. Scand J Infect Dis 1989; 21:
463–466.
42 Tauriainen S, Oikarinen S, Taimen K, et al. Temporal relationship between
human parechovirus 1 infection and otitis media in young children. J Infect Dis
2008; 198:35–40.
43 Legay V, Chomel JJ, Fernandez E, et al. Encephalomyelitis due to human
parechovirus type 1. J Clin Virol 2002; 25:193–195.
44 O’Regan S, Robitaille P, Mongeau JG, McLaughlin B. The hemolytic uremic
syndrome associated with ECHO 22 infection. Clin Pediatr (Phila) 1980;
19:125–127.
45 Maller HM, Powars DF, Horowitz RE, Portnoy B. Fatal myocarditis associated
with ECHO virus, type 22, infection in a child with apparent immunological
deficiency. J Pediatr 1967; 71:204–210.
46 Russell SJ, Bell EJ. Echoviruses and carditis. Lancet 1970; 1:784–785.
47 Birenbaum E, Handsher R, Kuint J, et al. Echovirus type 22 outbreak
associated with gastro-intestinal disease in a neonatal intensive care unit.
Am J Perinatol 1997; 14:469–473.opyright © Lippincott Williams & Wilkins. Unautho48 Abzug MJ, Keyserling HL, Lee ML, et al. Neonatal enterovirus infection:
virology, serology, and effects of intravenous immune globulin. Clin Infect
Dis 1995; 20:1201–1206.
49 Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus
infections with pleconaril. Clin Infect Dis 2001; 32:228–235.
50 Desmond RA, Accortt NA, Talley L, et al. Enteroviral meningitis: natural history
and outcome of pleconaril therapy. Antimicrob Agents Chemother 2006;
50:2409–2414.
51 Hyypia T, Horsnell C, Maaronen M, et al. A distinct picornavirus group
identified by sequence analysis. Proc Natl Acad Sci U S A 1992; 89:
8847–8851.
52 Stanway G, Kalkkinen N, Roivainen M, et al. Molecular and biological
characteristics of echovirus 22, a representative of a new picornavirus group.
J Virol 1994; 68:8232–8238.
53 Roivainen M, Piirainen L, Hovi T, et al. Entry of coxsackievirus A9 into host
cells: specific interactions with alpha v beta 3 integrin, the vitronectin
receptor. Virology 1994; 203:357–365.
54 Pulli T, Koivunen E, Hyypia T. Cell-surface interactions of echovirus 22. J Biol
Chem 1997; 272:21176–21180.
55 Joki-Korpela P, Marjomaki V, Krogerus C, et al. Entry of human parechovirus 1.
J Virol 2001; 75:1958–1967.rized reproduction of this article is prohibited.
